2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)-
- CAS No.
- 2369048-69-9
- Chemical Name:
- 2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)-
- Synonyms
- GNE-274;2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)-
- CBNumber:
- CB89825620
- Molecular Formula:
- C29H31NO4
- Molecular Weight:
- 457.56
- MDL Number:
- MOL File:
- 2369048-69-9.mol
- MSDS File:
- SDS
2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)- price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0181241 | GNE-274 98.00% | 2369048-69-9 | 1mg | $325 | 2026-06-04 | Buy |
| ChemScene | CS-0181241 | GNE-274 98.00% | 2369048-69-9 | 5mg | $975 | 2026-06-04 | Buy |
| ChemScene | CS-0181241 | GNE-274 98.00% | 2369048-69-9 | 10mg | $1571 | 2026-06-04 | Buy |
| ChemScene | CS-0181241 | GNE-274 98.00% | 2369048-69-9 | 25mg | $3250 | 2026-06-04 | Buy |
| ChemScene | CS-0181241 | GNE-274 98.00% | 2369048-69-9 | 50mg | $5200 | 2026-06-04 | Buy |
2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)- Chemical Properties, Uses, Production
Uses
GNE-274 is a structural analog of the ER degrader GDC-0927 and is a non-degrader. GNE-274 does not induce conversion of ER in breast cancer cell lines and functions as a partial ER agonist (partial ER agonist). GNE-274 increases the chromatin accessibility of ER-DNA binding sites, whereas GDC-0927 does not. GNE-274 is an effective ER ligand binding domain (LBD) inhibitor. GNE-274 can be used in cancer research.
Biological Activity
GNE-274 is a non-degrader that is structurally related to GDC-0927 (ER degrader). GNE-274 does not induce ER turnover and functions as a partial ER agonist in breast cancer cell lines. GNE-274 increase chromatin accessibility at ER-DNA binding sites, while GDC-0927 do not. GNE-274 is a potent inhibitor of ER-ligand binding domain (LBD). GNE-274 can be used for cancer research[1][2]. GNE-274 (0.1 nM-1000 nM; 4 hours) fails to trigger increased ER turnover in MCF7, MD-134, HCC1500 and CAMA cells[1].GNE-274 (1-1000 nM; 7-10 days) potently inhibits cellular proliferation, exhibiting greater potency than fulvestrant, 4-OHT, AZD9496, and GDC-0810 in E2-stimulated ER+ breast cancer cell lines[1].In transposaseaccessible chromatin sequencing (ATAC-seq) assay, GNE-274 increase chromatin accessibility at ER-DNA binding sites, it significantly alters chromatin accessibility at 594 sites. But GDC-0927 has considerably less impact on chromatin accessibility[1].
References
[1]. Jane Guan, et al. Therapeutic Ligands Antagonize Estrogen Receptor Function by Impairing Its Mobility. Cell. 2019 Aug 8;178(4):949-963.e18.[2]. Jane Guan, et al. Abstract NG05: Not all "SERDs" are equal: Context-independent ER degradation and full ER antagonism define the next generation of ER therapeutics. Cancer research.
2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)- Preparation Products And Raw materials
Raw materials
Preparation Products
2H-1-Benzopyran-6-ol, 3-(3-hydroxyphenyl)-4-methyl-2-[4-[(1-propyl-3-azetidinyl)methoxy]phenyl]-, (2S)- Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | 1-631-485-4226; 16314854226 | info@bocsci.com | United States | 9920 | 65 |
| ShangHai Caerulum Pharma Discovery Co., Ltd. | 18149758185 18149758185 | sales-cpd@caerulumpharma.com | China | 3493 | 58 |
| Suzhou youruike Chemical Pharmaceutical Technology Co., Ltd | 15317229551 | 15151849396@163.com | China | 959 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 50068 | 58 |




